D.C. Mun. Regs. tit. 22, r. 22-B1201

Current through Register Vol. 71, No. 49, December 6, 2024
Rule 22-B1201 - SCHEDULE I ENUMERATED
1201.1

The controlled substances listed in this section are included in Schedule I of the Act unless removed therefrom pursuant to Section 201 of the Act:

(a) Opiates: Unless specifically excepted or unless listed in another schedule, any of the following opiates including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
(1) 1-Methyl-4-phenyl-4-propionoxypiperidine (MPPP);
(2) 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
(3) 3-Methylfentanyl;
(4) 3-Methylthiofentanyl;
(5) Acetyl-Alpha-Methylfentanyl;
(6) Acetylmethadol;
(7) Allylprodine;
(8) Alphacetylmethadol except Levo-alphacetylmethadol
(9) Alphameprodine;
(10) Alphamethadol;
(11) Alpha-Methylfentanyl;
(12) Alpha-Methylthiofentanyl;
(13) Benzethidine;
(14) Betacetylmethadol;
(15) Beta-hydroxyfentanyl;
(16) Beta-hydroxy-3-Methylfentanyl;
(17) Betameprodine;
(18) Betamethadol;
(19) Betaprodine;
(20) Clonitazene;
(21) Dextromoramide;
(22) Diampromide;
(23) Diethylthiambutene;
(24) Difenoxin;
(25) Dimenoxadol;
(26) Dimepheptanol;
(27) Dimethylthiambutene;
(28) Dioxaphetyl butyrate;
(29) Dipipanone;
(30) Ethylmethylthiambutene;
(31) Etonitazene;
(32) Etoxeridine;
(33) Furethidine;
(34) Hydroxypethidine;
(35) Ketobemidone;
(36) Levomoramide;
(37) Levophenacylmorphan;
(38) Morpheridine;
(39) Noracymethadol;
(40) Norlevorphanol;
(41) Normethadone;
(42) Norpipanone;
(43) Para-fluorofentanyl;
(44) Phenadoxone;
(45) Phenampromide;
(46) Phenomorphan;
(47) Phenoperidine;
(48) Piritramide;
(49) Proheptazine;
(50) Properidine;
(51) Propiram;
(52) Racemoramide;
(53) Thiofentanyl;
(54) Thiophene;
(55) Tilidine; and
(56) Trimeperidine;
(b) Opium Derivates: Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Diacetylmorphine (heroin);
(9) Dihydromorphine;
(10) Drotebanol;
(11) Etorphine (except hydrochloride salt);
(12) Hydromorphinol;
(13) Methyldesorphine;
(14) Methyldihydromorphine;
(15) Morphine methylbromide;
(16) Morphine methylsulfonate;
(17) Morphine-N-Oxide;
(18) Myrophine;
(19) Nicocodeine;
(20) Nicomorphine;
(21) Normorphine;
(22) Pholcodine; and
(23) Thebacon;
(c) Hallucinogenic Substances: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers):
(1) 1-[1-(2-Thienyl)cyclohexyl]piperidine;
(2) 1- [1-(2-thienyl)cyclohexyl]pyrrolidine;
(3) 1-(1-Phenylcyclohexyl)-pyrrolidine,Pyrrolidine analog of phencyclidine, PCPy, PHP;
(4) (2C-C) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine;
(5) (2C-D) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;
(6) (2C-E) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;
(7) (2C-H) 2-(2,5-Dimethoxyphenyl)ethanamine;
(8) (2C-I) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine;
(9) (2C-N) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;
(10) (2C-P) 2-(2,5-Dimethoxy-4(n)-propylphenyl)ethanamine;
(11) (2C-T-2) 2-[4-(ethylthio)-2,5-dimethoxyphenyl)ethanamine;
(12) (2C-T-4)2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine;
(13) (2C-T-7) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine);
(14) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe);
(15) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine 25C-NBOMe); and
(16) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);
(17) 2,5-Dimethoxyamphetamine;
(18) 2,5-Dimethoxy-4-ethylamphetamine;
(19) 3,4-Methylenedioxymethamphetamine;
(20) 3,4-Methylenedioxyamphetamine;
(21) 3,4-Methylenedioxy-N-ethylamphetamine;
(22) 3,4,5-Trimethoxyamphetamine;
(23) 4-Bromo-2,5-dimethoxy-amphetamine;
(24) 4-Bromo-2,5-dimethoxyphenethylamine;
(25) 4-Methoxyamphetamine;
(26) 4-Methylaminorex;
(27) 4-Methyl-2,5-dimethoxyamphetamine;
(28) 5-flouro-UR-144 and XLR11[1-(5-Fluoro-pentyl)1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(29) 5-Methoxy-3,4-methylenedioxyamphetamine;
(30) 5-Methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);
(31) 5-Methoxy-N,N-dimethyltryptamine;
(32) Bufotenine;
(33) Diethyltryptamine;
(34) Dimethyltryptamine;
(35) N-Ethyl-1-phenylcyclohexylamine;
(36) Ibogaine;
(37) Lysergic acid diethylamide;
(38) Mescaline;
(39) N-Ethyl-1-phenylcyclohexylamine;
(40) N-Ethyl-3-piperidyl benzilate;
(41) N-Methyl-3-piperidyl benzilate;
(42) Parahexyl--7374; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6Hdibenzo[b,d]pyran; Synhexyl;
(43) Peyote;
(44) Psilocybin;
(45) Psilocyn; and
(46) Thiophene analog of phencyclidine;
(47) (2C-T) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine; OR 4-methylthio-2,5-dimethoxyphenethylamine;
(48) 4- methylthio-2,5-dimethoxyphenethylamine;
(49) (2C-B-butterFLY) 2-(10-Bromo-2,3,4,7,8,9 hexahydropyrano[2,3-g]chromen-5-yl)ethanamine;
(50) (2C-B-FLY) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine;
(51) (2C-B-hemiFLY, 2CB-5-hemiFLY) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine;
(52) (2C-B-FLY-NBOMe) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane;
(53) (2C-B-NBOMe, 2,5B-NBOMe) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4- bromo-N-(2-methoxybenzyl) phenethylamine
(54) 2CBCB-NBOMe N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa -1,3,5-trien-7-yl]methanamine;
(55) 2C-C-NBOMe, 2,5C-NBOMe 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
(56) 2C-H-NBOMe, 2,5H-NBOMe 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;
(57) 2C-I-NBOH, 2,5I-NBOH N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine;
(58) 2C-I-NBOMe, 2,5INBOMe, 2,5I-NBOMe, 25I-NBOMe, NBOMe-2C-I, BOM-CI 2- 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
(59) (2CBCB-NBOMe) N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
(60) (2C-H-NBOMe, 2,5H-NBOMe) 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
(61) (2C-I-NBOH, 2,5I-NBOH) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine;
(62) 2C-TFM-NBOMe) 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-ethoxyphenyl)methyl]ethanamine;
(63) (25I-NBF) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethanamine;
(64) (25I-NBMD, NBMD-2C-I, Cimbi-29) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2,3ethylenedioxyphenyl)methyl]ethanamine;
(65) (3C-B-FLY) 2-(4-bromo-2,3,6,7-tetrahydrofurobensofur an-8-yl)-1-methyl-ethylamine;
(66) (4-CAB, AEPCA) 4-Chlorophenylisobutylamine; OR 1-(4-chlorophenyl)butan-2-amine; OR 4-chloro-a-ethylphenethylamine;
(67) (4-FA, PAL-303, Flux, Flits, R2D2) para-fluoroamphetamine; OR 4-fluoroamphetamine; OR (RS)-1-(4-Fluorophenyl)propan-2-amine;
(68) (5-APB) 5-(2-Aminopropyl)benzofuran;
(69) (5-APDB) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran; 1-(2,3-dihydro-1-benzofuran-5-yl)propan-2-amine; 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (3-Desoxy-MDA, EMA-4)
(70) (6-APB; Benzofury) 6-(2-aminopropyl)benzofuran; OR 1-benzofuran-6-ylpropan-2-amine;
(71) (6-APDB) 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran;
(72) (APB) ((2-aminopropyl)benzofuran); OR [(2-aminopropyl)benzofuran]; OR (2-aminopropyl)benzofuran;
(73) (APDB) ((2-aminopropyl)-2,3-dihydrobenzofuran); OR [(2-aminopropyl)-2,3-dihydrobenzofuran]; OR (2-aminopropyl)-2,3-dihydrobenzofuran;
(74) (bromo-dragonFLY) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine; OR bromo-benzodifuranyl-isopropylamine;
(75) (DOB) 2,5-Dimethoxy-4-bromoamphetamine; OR 1-(4-Bromo-2,5- dimethoxyphenyl)-2-aminopropane;
(76) (DOC) 2,5-Dimethoxy-4-chloroamphetamine; OR 1-(4-chloro-2,5- dimethoxy-phenyl)propan-2-amine; OR 4-chloro-2,5-dimethoxyamphetamine;
(77) (DOI) 2,5-dimethoxy-4-iodoamphetamine; OR 1-(2,5-dimethoxy-4- iodophenyl)-propan-2-amine; OR 4-iodo-2,5-dimethoxyamphetamine;
(78) DOM, STP 4-methyl-2,5-dimethoxy-amphetamine; OR 4-methyl-2,5-dimethoxy-a-methylphenethylamine;
(79) (Fluoroamphetamine);
(80) MDA 3,4-methylenedioxy amphetamine;
(81) MDMA 3,4-methylenedioxymethamphetamine;
(82) MDE, MDEA3,4-methylenedioxy-N-ethylamphetamine; OR N-ethylalpha-methyl-3,4(methylenedioxy)phenethylamine;
(83) Mescaline 3,4,5-trimethoxyphenethylamine;
(84) (Mescaline-NBOMe) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine; OR 3,4,5-trimethoxy-N-(2-methoxybenzyl)phenethylamine;
(85) (PMMA, 4-MMA) para-Methoxy-N-methylamphetamine; OR 4-methoxy-N- methylamphetamine; OR 1-(4-methoxyphenyl)-N-methyl-propan-2-amine;
(86) TMA, 3,4,5-trimethoxyamphetamine;
(87) 2,5-Dimethoxy-4-ethylamphetamine, (DOET, DOE);
(88) Eticyclidine (PCE, CI-400);
(89) N-Ethyl-mda; Eve (amphetamine); 3,4-Methylenedioxyethylamphetamine; 3,4-Methylenedioxy-N-ethylamphetamine;
(90) 4-Methylthioamphetamine (4-MTA);
(91) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, (2C-B-NBOMe);
(92) 4- Methyl- 2,5-dimethoxyphenethylamine, (2C-D);
(93) 2-(4-Methyl-2,5-dimethoxyphenyl)-N- (2-methoxybenzyl)ethanamine, (2C-D-NBOMe);
(94) 4-Ethyl- 2,5-dimethoxyphenethylamine, (2C-E);
(95) 2-5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)ethanamine, (2C-I-NB0Me);
(96) 1-(Benzofuran-5-yl)-N-methylpropan-2-amine, (5-MAPB) (1-(benzofuran-5-yl)-N-methylpropan-2-amine);
(97) N-Methy\-(6-bromo-3,4- methylenedioxypheny1)propan-2-amine, (6-Br-MDMA);
(98) 1-(6-chloro-1,3-benzodioxol-5-yl)-N-methylpropan-2-amine, 6-Chloro-MDMA (6-Cl-MDMA, 2-Cl-4,5-MDMA);
(99) (AB-FUBINACA) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H -indazole-3-carboxamide;
(100) (ADB-PINACA) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;
(101) (ADBICA) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide;
(102) (APICA) N-(1-adamantyl)-1-pentylindole-3-carboxamide;
(103) (CUMYL-THPINACA) N-(2-Phenypropan-2-yl)-1-(tetrahydropyran 4- ylmethyl)-1H-indazole-3-carboxamide;
(104) (EAM-220O1); (5"-fluoro-JWH-210) (1-(5-Flouropentyl)-1H-indol-3-yl)(4-ethylnaphthalen-1-yl)methadone;
(105) (FUB-JWH-018) (1-(4-Fluorobenzyl)-1H-indol-3-yl)(naphthalene-1-yl)methadone;
(106) (FUB-PB-22); (UNII-DS46154N3F); (DS46154N3F) quinolin-8-yl 1-[(4-fluorophenyl)methyl]indole-3-carboxylate;
(107) (MDMB-CHMICA) N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2yl)-1-(cyclohexylmethyl)-1H-indole-3-carboxamide;
(108) (MDMB-FUBINACA) N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1(4-fluorobenzyl)-1H -indazole-3-carboxamide;
(109) (PX-2) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;
(110) (2-FMC) 1-(2-flourophenyl)-2-methylaminopropan-1-one;
(111) (2-MMC) 1-(2-methylphenyl)-2-methylaminopropan-1-one;
(112) (3,3-DMMC) 1-(3,4- dimethylphenyl)-2-methylaminopropan-1-one;
(113) (3-CMC) 1-(3-chlorophenyl)-2-methylaminopropan-1-one;
(114) (3-MeOMC) 1-(3-methoxyphenylaminopropan-1-one;
(115) (3-MMC) 1-(3-methylphenyl)-2-methylaminopropan-1-one;
(116) (4-BMC) 1-(4-bromophenyl)-2-methylaminopropan-1-one;
(117) (4-CMC) 1-(4-chlorophenyl)- 2-methylaminopropan-1-one;
(118) (4-MMC) 4-methyl methcathinone or 4-methyl ephedrone;
(119) (1-butyl-1H -indol-3-yl)(4-methylnaphthalen-1-yl)methanone;
(120) [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-1-naphthalenyl-methanone;
(121) 3-(4-methoxyphenyl)-2-methyl-1-[(2-(4-morpholinyl)ethyl)-1H-indol-3-yl]-methanone;
(122) 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone;
(123) (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol- 3-yl]-methanone;
(124) [1-[(1-methyl-2-piperdinyl)methyl]-1H-indol-3-yl]tricycle[3.3.1.13,7]dec-1-yl-methanone;
(125) 1-naphthalenyl(1-propyl-1H -indol-3-yl)-methanone;
(126) 5-[3-(1-naphthoyl)-1H-indole-1-yl]pentanenitrile;
(127) 3-(1-naphthenylmethyl)-1-pentyl-1H-indole;
(128) (2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone;
(129) 1-naphthalenyl[1-(4-penten-1-yl)-1H-indol-3-yl]-methanone;
(130) (4-bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone;
(131) (4-fluoronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone;
(132) (2-methyl-1-phenyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
(133) 2-(2-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone;
(134) [1-(5-chloropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone;
(135) (adamantan-1-yl)(1-pentyl-1H-indol-3-yl)-methanone;
(136) (2-iodo-5-nitrophenyl)-[1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl]-methanone;
(137) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclo-propyl)methanone;
(138) [1-(5-fluoropentyl-1H-indol-3-yl)](2,2,3,3-tetramethylcyclo-propyl)methanone;
(139) [1-(2-morpholinoethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(140) 1-[(tetrahydro-2H -pyran-4-yl)methyl]-1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)methanone;
(141) 1-pentyl-N-tricyclo[3.3.1.13,7]dec -1-yl-1H-indole-3-carboxamide;
(142) 1-pentyl-N-tricyclo[3.3.1.13,7]dec -1-yl-1H-indazole-3-carboxamide;
(143) 1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide;
(144) [1-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(145) (1-isopentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone;
(146) 1-(5-fluoropentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole -3-carboxamide;
(147) (1-pentyl-1H-indol-3-yl)(4-propyl-1-naphthalenyl)-methanone;
(148) [1-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(149) (4-methyl-naphthalen-1-yl)[1-(pent -4-en-1-yl)-1H-indol-3-yl]methanone;
(150) (2-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone;
(151) (3-methoxy-phenyl)(1-pentyl-1H-indol-3-yl)methanone;
(152) [1-(5-fluoropentyl)-1H-indol-3-yl](4-ethyl-1-naphthalenyl)-methanone;
(153) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;
(154) quinolin-8-yl 1-(5-fluoropentyl-1H-indole-3-carboxylate;
(155) 1-(cyclohexylmethyl)-8-quinolinyl-ester-1H-indole-3-carboxylic acid;
(156) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;
(157) 1-(5-fluoropentyl)-N-(naphtha lene-1-yl)-1H-indole-3-carboxamide;
(158) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H -indazole-3-carboxamide;
(159) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole -3-carboxamide;
(160) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide;
(161) 2-iodophenyl)(1-pentyl-1H -indol-3-yl)methanone;
(162) [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone;
(163) 1-pentyl-N-(naphthalene-1-yl)-1H -indole-3-carboxamide;
(164) 1-(5-chloropentyl)-1H-indol-3-yl](4-methyl-1-naphthalenyl)-methanone;
(165) (4-methyl-naphthalen-1-yl)[2-methyl-1-(pent-4-en-1-yl)-1H-indol-3-yl)]methanone;
(166) [1-(5-fluoropentyl)-1H-indol-3-yl](o-tolyl)methanone;
(167) (2-ethylphenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone;
(168) [1-(5-chloropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone;
(169) [1-(5-bromopentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone;
(170) (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalene-1-yl)methanone;
(171) 1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(172) (1-(1-methylazepan-2-yl)-1H -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(173) 4-hydroxy-3,3,4-trimethyl-1-(1-pentyl-1H-indol-3-yl)pentan-1-one;
(174) [1-(4-fluoropentyl)-1H-indol-3-yl]-1-naphthenyl-methanone;
(175) 2-(2-iodophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
(176) (1-hexyl-1H -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(177) (2,2,3,3-tetramethylcyclopropyl)[1-(4,4,4-trifluorobutyl)- 1H-indol-3-yl]methanone;
(178) 7-methoxy-1-(2-morpholinoethyl)-N-((1S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H -indole-3-carboxamide;
(179) (4-fluorobenzyl)-1H-indole-3-quinolin-8-yl Carboxylate;
(180) 1-(4-fluorobenzyl)-1H-indole-3-naphthalen-1-yl Carboxylate;
(181) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole -3-carboxamide;
(182) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;
(183) (1-(4-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(184) 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)methanone;
(185) N-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide;
(186) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H -indazole-3-carboxamide;
(187) naphthalene-1-yl(9-pentyl-9H-carbazol-3-yl)methanone;
(188) naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;
(189) methyl 3-methyl-2-(1-pentyl-1H-indazole-3-carboxamido;
(190) methyl 2-(1-5-fluoropentyl)-1H-indazole-3-caboxamido) methylbutanoate;
(191) N-benzyl-1-pentyl-1H-indole-3-carboxamide;
(192) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide;
(193) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate;
(194) quinolin-8-yl 1-pentyl-1H-indazole-3-carboxylate;
(195) quinolin-8-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate;
(196) naphthalene-2-yl 1-(2-fluorophenyl)-1H-indazole-3-carboxylate;
(197) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide;
(198) (1-(4-flourobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(199) N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H -indole-3-carboxamide;
(200) N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H -indazole-3-carboxamide;
(201) methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl-L-valinate;
(202) N-[(1-(cyclohexylmethyl)-1H-indazole-3yl)carbonyl]- 3-methyl-L-valine, methyl ester;
(203) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)- 3,3-dimethylbutanoate;
(204) (1-(5-fluoropentyl)-1H-benzo[d]imidazole-2-yl)(naphthalene -1-yl)methanone;
(205) (1-(4-fluorobenzyl)-1H-indol-3-yl)(napthalen-1-yl)methanone;
(206) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate;
(207) quinolin-8-yl1-(4-fluorobenzyl)-1H-indazole-3-carboxylate;
(208) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;
(209) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H -indole-3-carboxamide;
(210) 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylheptyl-2-yl)phenol;
(211) 3-hydroxy-2[3-methyl-6-(1-methylethyenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;
(212) 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl] -6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol;
(213) 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone;
(214) 3-(2-(hydroxymethyl)-2,3-dihydro-1H -inden-4-yloxy)phenyl 4,4,4-trifluorobutane-1-sulfonate;
(215) N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide;
(216) N-[3-(2-methoxyethyl)-4,5-dimethylthiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-carboxamide;
(217) 5-chloro-3-ethyl-N-[4-(piperidin-1-yl)phenethyl)-1H -indole-2-carboximide;
(218) N-[4-(dimethylamino)phenethyl]-3-ethyl-5-fluoro-1H-indole-2-carboximide;
(219) N-(1-benzylpyrrolidin-3-yl)-5-chloro-3-ethyl-1H -indole-2-carboxamide;
(220) [5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalene-1-yl)methanone;
(221) (3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexyl-carbamate;
(222) 5-(biphenyl-4-ylmethyl)-N,N-dimethyl-1H-tetrazole-1-carboxamide;
(223) 6-methyl-2-(p-tolylamino) -4H-benzo[d][1,3]oxazin-4-one;
(224) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester;
(225) 4-hydroxy-N-(4-hydroxyphenethyl)-3-(pentylamino)-benzamide; and
(226) 3' -carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-ylcyclohexylcarbamate;
(d) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, or mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system including its salts, isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible, within the specific chemical designation:
(1) Cyclobarbital; Hexemal; Cyclobarbitone;
(2) Etaqualone; Athinazone; Ethinazone; 3-(2-ethylphenyl)-2-methylquinazolin-4-one;
(3) Gamma-Hydroxybutyric Acid [other names include GHB; gamma-hydroxybutyrate; 4-hyrdroxybutyrate; 4-hydroxybutanoic acid; socium oxybate; sodium xybutyrate];
(4) Mecloqualone; and
(5) Methaqualone;
(e) Stimulants: Unless specifically excepted or unless listed in another schedule, a ny material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Alpha-ethyltryptamine;
(2) Alpha-methyltryptamine;
(3) Aminorex;
(4) Brolamfetamine, bromo-DMA, 2,5-Dimethoxy-4-bromoamphetamine, Dimethoxybromoamphetamine (DOB);
(5) 1,4-dibenzylpiperazine;
(6) 1-(4-bromo-2,5-dimethoxybenzyl)-piperazine;
(7) 1-(4-fluorophenyl)-piperazine;
(8) 1-(2-methoxyphenyl)-piperazine;
(9) 1-(4-chlorophenyl)-piperazine;
(10) 1-(4-methoxyphenyl)-piperazine;
(11) 1-(3-methylbenzyl)piperazine;
(12) 1-benzyl-4-methylpiperazine;
(13) 8-methyl-8-azabicyclo[3.2.1]octan-3-yl 4-fluorobenzoate;
(14) methyl 3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate ;
(15) Cathinone; Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways:
(A) By substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(B) By substitution at the 3-position with an alkyl substituent; or
(C) By substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;
(16) 2-diphenylmethylpyrrolidine, including 2-Benzylhydrylpyrrolidin, (S)-(-)-2-(diphenylmethyl)pyrrolidine, (S)-2-diphenylmethylpyrrolidine; (2S)-2-Benzylhydrylpyrrolidine; (2S) diphenylmethylpyrrolidine;
(17) Fenethylline;
(18) Mephe drone (4-methyl-N-methylcathinone), BZ-6378, 4-methylephedrone;
(19) Methcathinone, including 4-MEC 4-methyl-N-ethylcathinone, 4-methylethcathinone, para-methyl-N-ethylcathinone, para-methylethcathinone, 4-methyl-ethylcathinone;
(20) Methylenedioxypyrovalerone (MDPV);
(21) Methylone;
(22) N-Benzylpiperazine, (BZP) benzylpiperazine, N-benzylpiperazine;
(23) N-ethylamphetamine;
(24) N-Hydroxy-3, 4-methylenedioxyamphetamine;
(25) N, N-Dimethylamphetamine;
(26) 4-methyl-N-ethylcathinone ("4-MEC");
(27) 4-methyl-alpha-pyrrolidinopropiophenone ("4-MePPP");
(28) Alpha-pyrrolidinopentiophenone ("a-P VP"), (a-PVP, alpha-PVP), a-Pyrrolidinopentiophenone, 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, alpha-pyrrolidinovalerophenone, a-pyrrolidinovalerophenone;
(29) 1-(1, 3-benzodio xol-5-yl)-2-(methylamino)butan-1-one ("butylone");
(30) 2-(methylamino)-1-phenylpentan-1-one ("pentedrone");
(31) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one ("pentylone");
(32) 4-fluoro-N-methylcathinone ("4-FMC"), including 4-ethylmethcathinone, 4-ethyl-methcathinone, Flephedrone, 4-fluoromethcathinone;
(33) 3-fluoro-N-methylcathinone ("3-FMC"), 3-fluoromethcathinone;
(34) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone");
(35) Alpha-pyrrolidinobutiophenone ("a-PBP") (a-PBP, alpha-PBP) alpha-Pyrrolidinobutiophenone, a-Pyrrolidinobutiophenone, (RS)1-phenyl-2-(1-pyrrolidinyl)-1-pentanone;
(36) 2-DPMP, including desoxypipradrol, diphenylprolinol, 2-Diphenylmethylpiperidine, 2-benzhydrylpiperidine;
(37) 2-FMC, 2-fluoromethcathinone;
(38) 3,4-DMMC, 3,4-dimethylmethcathinone;
(39) 4-MBC, Benzedrone, (±)-1-(4-methylphenyl)-2-(benzylamino)propan-1-one, 4-methyl-N-benzylcathinone,N-benzyl-4-methylcathinone, 1-(4 methylphenyl)-2-benzyla-minopropan-1-one;
(40) 4-MeMABP, 4-methylbuphedrone, (2-Methylamino-1-(4-methylphenyl)butan-1-one), 2-methylamino-1-(4-methylphenyl)butan-1-one;
(41) a-PPP, alpha-PPP, alpha-pyrrolidinopropiophenone, a-pyrrolidinopropiophenone;
(42) Buphedrone, a-methylamino-butyrophenone, 2-(methylamino)-1-phenylbutan-1-one, alpha-methylamino-butyrophenone;
(43) Butylone, bk-MBDB, beta -Keto-N-methylbenzodioxolylpropylamine, beta-Keto-N-methyl-3,4-benzodioxyolybutanamine;
(44) D2PM, diphenyl-2-pyrrolidinyl-methanol;
(45) Dimethocaine, (3-diethylamino-2,2-dimethylpropyl)-4-aminobenzoate;
(46) DMBDB, bk-DMBDB,dibutylone, 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-Dibutylone) one;
(47) DMEC, dimethylethcathinone;
(48) DMMC, dimethylmethcathinone;
(49) Ephedrone (sometimes used as another name for methcathinone) 2-(methylamino)-1-phenylpropan-1-one; OR 2-methylamino-1-phenylpropan-1-one;
(50) Ethcathinone, 2-ethylamino-1-phenyl-propan-1-one;
(51) Ethylethcathinone;
(52) Ethylmethcathinone;
(53) Ethylone 3,4-methylenedioxy-N-ethylcathinone; OR 3,4-methylenedioxyethylcathinone; OR 3,4-methylenedioxy-ethylcathinone; OR 3,4-methylenedioxyethcathinone;
(54) Eutylone beta -Keto-Ethylbenziodioxolylbutanamine;
(55) Fluorococaine;
(56) Fluoroethcathinone;
(57) Fluoroisocathinone;
(58) Fluoromethcathinone;
(59) HMMC 3-methoxymethcathinone;
(60) Isopentedrone;
(61) MaPPP, 4-MePPP, MPPP 4-methyl-alpha -pyrrolidinopropiophenone; OR 4-methyl-a-pyrrolidinopropiophenone; OR methylpyrrolidinopropiophenone; OR Methyl-pyrrolindinopropiophenone;
(62) MBP Methylbuphedrone;
(63) MBZP 1-methyl-4-benzylpiperazine ;
(64) MDAI methylenedioxy-aminoindane; OR 5,6-methylenedioxy-2-aminoindane;
(65) MDAT 6,7-methylenedioxy-2-aminotetralin;
(66) MDDMA Dimethylone;
(67) MDMC Methylenedioxymethcathinone;
(68) MDPBP 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone; OR 3,4-methylenedioxy-a-pyrrolidinobutiophenone;
(69) MDPPP 3,4-methylenedioxy-a-pyrrolidinopropiophenone; OR (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone; OR 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone;
(70) MDPV, MDPK 3,4-methylenedioxypyrovalerone; OR methylenedioxypyrovalerone;
(71) MEC Methylethcathinone;
(72) Mephedrone, 4-MMC 4-methylmethcathinone; OR 4-methylephedrone; OR (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one;
(73) Metamfepramone, N,N-DMMC N,N -dimethylcathinone;
(74) Methedrone, Bk-PMMA, PMMC para-methoxymethcathinone; OR 4-methoxymethcathinone; OR methoxyphedrine; OR (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one;
(75) Methylmethcathinone;
(76) Methylone, bk-MDMA, MDMC 3,4-methylenedioxy-N-methylcathinone; OR 3,4-methylenedioxymethcathinone; OR 3,4-methylenedioxymethylcathinone;
(77) MOMC Methoxymethcathinone;
(78) MOPPP 4-methoxy-alpha-pyrrolidinopropiophenone; OR 4-methoxy-a-pyrrolidinopropiophenone;
(79) MPBP 4-methyl-alpha-pyrrolidinobutyrophenone; OR 4-methyl-a-pyrrolidinobutryophenone; OR 4-methyl-alpha-pyrrolidinobutiophenone; OR 4-methyl-a-pyrrolidinobutiophenone;
(80) NRG-1, Naphyrone naphthylpyrovalerone;
(81) NRG-2;
(82) Pentedrone a-methylamino-Valerophenone; OR 2-(methylamino)-1-phenyl-1-pentanone; OR 2-methylamino-1-phenyl-1-pentanone;
(83) Pentylone beta-Keto-N-methylbenzodioxolylpentanamine; OR beta -keto-ethylbenzodioxolylpentanamine;
(84) 1-(2-Fluorophenyl)propan-2-amine, (2-FA);
(85) N-Methyl-1-(benzofuran-2-yl)propan-2-amine, (2-MAPB);
(86) 1-(3-Fluorophenyl)propan-2-amine, (3-FA), (RS)-1-(3-Fluorophenyl)propan-2-amine;
(87) (RS)-1-(3-fluorophenyl)-N-methylpropan-2-amine, (3-FMA);
(88) 1-(4-Chlorophenyl)propan-2-amine, para-Chloroamphetamine (PCA), 4-chloroamphetamine (4-CA);
(89) Levmetamfetamine or (-)-Methamphetamine; L-Methylamphetamine or (-)-Deoxyephedrine or R(-)-N-Methylamphetamine;
(90) 1-(3-fluorophenyl)-2-(methylamino)-1-propanone;
(91) 1-(4-fluorophenyl)-2-(methylamino)-1-propanone;
(92) 1-(4-methoxyphenyl)-2-(methylamino)-1-propanone;
(93) 2-(ethylamino)-1-(4-methoxyphenyl)-1-propanone;
(94) 1-(2-naphthalenyl)-2-(1-pyrrolidinyl)-1-pentanone;
(95) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-butanone;
(96) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-pentanone;
(97) 2-(ethylamino)-1-phenyl-1-propanone ;
(98) 1-phenyl-2-(1-pyrrolidinyl)- 1-propanone;
(99) 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-propanone;
(100) 1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-1-propanone;
(101) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-propanone;
(102) 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone;
(103) 2-amino-1-(4-fluoro)-1-propanone;
(104) 2-(ethylamino)-1-(4-ethylphenyl)-1-propanone;
(105) 2-(dimethylamino)-1-phenyl-1-propanone;
(106) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-butanone;
(107) 1-(methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone;
(108) 1-(methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone;
(109) 2-(methyla mino)-1-phenyl-1-butanone;
(110) 2-(methylamino)-1-p-tolyl-1-butanone;
(111) 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-butanone;
(112) 1-(3,4-dimethylphenyl)-2-(methylamino)-1-propanone;
(113) 1-phenyl-2-(1-pyrrolidinyl)-1-butanone;
(114) 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-propanone;
(115) 1-(4-methylphenyl)-2-(benzylamino)-1-propanone;
(116) 1-(1-naphthy)-2-(1-pyrrolidinyl)-1-pentanone;
(117) 1-(1,3-benzodioxol-5-yl)-2-(benzylamino)-1-propanone;
(118) 1-(1,3-benzodioxol-5-yl)-2-(benzylamin o)-1-butanone;
(119) 1-(1,3-benzodioxol)-2-[hydroxy(methyl)-amino]-1-propanone;
(120) 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-butanone;
(121) 2-(ethyl(methyl)amino)-1-phenyl-butanone;
(122) 2-(ethyl(methyl)amino-1-phenyl-1-propanone;
(123) 2-(methylamino)-1-m-tolyl-1-propanone;
(124) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)-1-pentanone;
(125) 1-(4-fluorophenyl)-2-(methylamino)-1-butanone;
(126) 1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)-1-butanone;
(127) 1-(4-ethylphenyl)-2-(pyrrolidin-1-yl)-1-butanone;
(128) 1-(4-methoxy-3-methylphenyl)-2-(methylamino)-1-propanone;
(129) 2-(ethylamino)-1-(3-methylphenyl)-1-propanone;
(130) 2-amino-(1H-indol-5-yl)propan-1-one;
(131) 1-phenyl-2-(piperidin-1-yl)butan-1-one;
(132) 2-methylamino-1-(2,4,5-trimethylphenyl)-propan-1-one);
(133) 1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one;
(134) 1-(benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)pentan-1-;
(135) 1-(2-fluorophenyl)-N-methyl-propan-2-amine;
(136) 1-(2-fluorophenyl)-propan-2-amine;
(137) 1-(3-fluorophenyl)- propan-2-amine;
(138) 1-(3-fluorophenyl)-N-methyl-propan-2-amine;
(139) N-ethyl-N-methyl-1-phenylpropan-2-amine;
(140) 1-(benzofuran-4-yl)propan-2-amine;
(141) 1-(2,3-dihydrobenzofuran-5-yl)proan-2-amine;
(142) 1-(2,3-dihydrobenzofuran-6-yl)proan-2-amine;
(143) N,N-dimethyl-1-phenylpropan-2-amine;
(144) 5,6,7,8-tetrahydrobenzo[1,3] -benzodioxol-7-amine;
(145) a-methyl-4-(methylthio)-benzene-ethanamine;
(146) 1-(4-chlorophenyl) -propan-2-amine;
(147) 1-(2,4,6-trimethoxyphenyl)-propan-2-amine;
(148) 1-(2,4,5-trimethoxyphenyl)-propan-2-amine;
(149) 1-(2,5-dimethylphenyl) -propan-2-amine;
(150) 1-(3,4-dimethylphenyl)-propan-2-amine;
(151) N-(1-phenylpropan-2-yl)propan-1-amine;
(152) 4-(2-aminopropyl)phenol;
(153) 3,4-methylenedioxy-N,N-dimethyl-amphetamine;
(154) N-ethyl-1-(4-methoxyphenyl)propan-2-amine;
(155) 6,7-dihydro-5H-inden[5,6-d][1,3]dioxol-6-amine;
(156) 5-methoxy-6-methyl-2,3-dihydro-1H -inden-2-amine;
(157) N-methyl-6,7-dihydro-5H-cyclopenta[1,3]-benzodioxol-6-amine;
(158) N-methyl-2,3-dihydro-1H-inden-2-amine ;
(159) 2-[4-(2-fluoroethylthio)-2,5- dimethoxyphenyl]ethanamine;
(160) 8-bromo-2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b']difuran-4-ethanamine;
(161) 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)-methyl-benzene-ethamine;
(162) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)-ethanamine;
(163) 2-(2,5-dimethoxy-3,4-dimethylphenyl)-ethanamine;
(164) 2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)-ethanamine;
(165) 2-(2,5-dimethoxy-3,4-dimethylphenyl)-N-(2- methoxybenzyl)-ethanamine;
(166) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)-ethanamine;
(167) 2-(2,5-dimethoxyphenyl-4-nitro)-N-[(2-methoxyphenyl)methyl]-ethanamine;
(168) 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine;
(169) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine;
(170) 1-(4-bromo-2,3,6,7-terahydrofuro[2,3-f]benzofuran-8-yl)propan-2-amine;
(171) (2,5-dimethoxyphenyl)-propan-2-amine;
(172) 1-[4-(ethylthio)-2,5-dimethoxyphenyl)propan-2-amine;
(173) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine;
(174) 1-[2,5-dimethoxy-4-(propylthio)phenyl]propan-2-amine;
(175) 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine;
(176) N-benzyl-2-phenylethanamine;
(177) N,N-dimethyl-2-phenylethanamine;
(178) 6-chloro-aminotetralin;
(179) 2-phenethylamine;
(180) 2-phenyl-propan-1-amine;
(181) 1-methylamino-1-(3,4-methylendioxy-phenyl)propane;
(182) N-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine;
(183) 1-(2-methoxyphenyl)-N-methylpropan-2-amine;
(184) 2-(4-(allyloxy)-3,5-dimethoxyphenyl)ethanamine;
(185) 4-methylhexan-2-amine;
(186) 4-methyl-5-phenyl-2-amino-oxazoline;
(187) (3-dimethylamino-2,2-dimethylpropyl)-4-aminobenzoate;
(188) 1-(4-fluorophenyl)-2-(methylamino)-propan-1-ol;
(189) 4-methyl-5-p-tolyl-4,5-dihydrooxazol-2-amine;
(190) 1-phenyl-2-(pyrrolidin-1-yl) propan-1-ol;
(191) 1-(3-methoxyphenyl)-N-propylcyclohexan-amine;
(192) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone;
(193) 1-phenylcyclohexan-amine;
(194) 1-[1-(benzothiophen-2-yl)cyclohexyl]piperidine;
(195) 1-(1-p-tolylcyclohexyl)-piperidine ;
(196) 1-(4-methoxyphenyl)-N-propylcyclohexan-amine;
(197) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine;
(198) 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine;
(199) 1-phenyl-N-propylcyclohexanamine;
(200) N-(2-methoxyethyl)-1-phenylcyclohexan-amine;
(201) N-(2-ethoxyethyl)-1-phenylcyclohexan-amine;
(202) N-(3-methoxypropyl)-1-phenylcyclohexan-amine;
(203) 3-[1-(piperidin-1-yl)cyclohexyl]-phenol;
(204) 2-(methoxyphenyl)-2-(methylamino)cyclohexanone;
(205) N-ethyl-1-(thiophen-2-yl)cyclohexanamine;
(206) (2-(2-chlorophenyl)-2-(ethylamino)-cyclohexanone);
(207) 2-(diphenylmethyl)-piperidine;
(208) 2-benzhydrylpyrrolidine;
(209) a,a-diphenyl-(pyrrolidin-2-yl)methanol;
(210) methyl 2-(3,4-dichlorophenyl)-2-(piperdin-2-yl)acetate;
(211) methyl 2-(3-chlorophenyl)-2-(piperidin-2-yl)acetate;
(212) methyl 2-(piperidin-2-yl)-2-p-tolylacetate; and
(213) ethyl 2-phenyl-2-(piperidin-2-yl)acetate;
(f) Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers):
(1) Classified Synthetic Cannabinoids:
(A) Adamantoylindoles or adamantoylindazoles, including adamantyl carboxamide indoles and adamantyl carboxamide indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl)indazole, 3-(2-adamantoyl)indole, N-(1-adamantyl)-1H-indole-3-carboxamide, or N-(1-adamantyl)-1H-indazole-3-carboxamide by substitution at the nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including the following: 2NE1, 5F-AKB-48, AB-001, APINACA and AKB-48, AM-1248, JWH-018 adamantyl carboxamide, STS-135;
(B) Benzoylindoles- any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following: AM-630, AM-661, AM-679, AM-694, AM-1241, AM-2233, RCS-4 or SR-19, WIN 48,098 (Pravadoline);
(C) Cyclohexylphenols- any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent, including, but not limited to, the following: CP 47,497, CP 47,497 C8 homologue, CP 55,490, CP 55,940, CP 56,667, cannabicyclohexanol;
(D) Cyclopropanoylindoles- any compound structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent;
(E) Naphthoylindoles- any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2201, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55,212;
(F) Naphthoylnaphthalenes- any compound structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent, including CB-13;
(G) Naphthoylpyrroles- any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;
(H) Naphthylmethylindenes - any compound containing a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-171, JWH-176, JWH-220;
(I) Naphthylmethylindoles- any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-175, JWH-184, JWH-185, JWH-192, JWH-194, JWH-195, JWH-196, JWH-197, JWH-199;
(J) Phenylacetylindoles- any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following: Cannabipiperidiethanone, JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, or SR-18;
(K) Quinolinylindolecarboxylates- any compound structurally derived from quinolin-8-yl-1H-indole-3-carboxylate by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the quinoline ring to any extent, including the following: BB-22, 5-Fluoro-PB-22, and PB-22;
(L) Tetramethylcyclopropanoylindoles- any compound structurally derived from 3-tetramethylcyclopropanoylindole, 3-(1-tetramethylcyclopropyl)indole, 3-(2,2,3,3-tetramethylcyclopropyl)indole or 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropanoyl ring to any extent, including the following: 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-UR-144, A-796,260, A-834,735, AB-034, UR-144, and XLR11; and
(M) Tetramethylcyclopropane-thiazole carboxamides- any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including A-836,339; and
(2) Unclassified Synthetic Cannabinoids:
(A) AM-087 (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(B) A M-356 (methanandamide); (5Z,8Z ,11Z ,14Z)-N- [(1R)-2-hydroxy-1-methylethyl] icosa-5,8,11,14-tetraenamide; or arachidonyl-1'- hydroxy-2'-propylamide;
(C) (5Z,8Z,11Z,14Z)-N-[(1R)-2-hydroxy-1-methylethyl] icosa-5,8,11,14-tetraenamide; or arachidonyl-1'-hydroxy-2'-propylamide;
(D) AM-411(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(E) AM-855(4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8, 9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol;
(F) AM-905(6aR,9R,10aR)-3-[(E)-hept -1-enyl]-9-(hydroxymethyl) -6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;
(G) AM-906(6aR,9R,10aR)-3-[(Z)-hept -1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;
(H) AM-2389(6aR,9R,10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol;
(I) BAY38-7271(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate;
(J) CP 50,556-1 (Levonantradol);
(K) 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6, 6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-;
(L) octahydrophenanthridin-1-yl] acetate; or [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a -octahydrophenanthridin-1-yl]acetate;
(M) HU-210(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-;
(N) (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol; or [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol;
(O) HU-211 (Dexanabinol);
(P) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a -tetrahydrobenzo[c]chromen-1-ol;
(Q) HU-2433-dimethylheptyl-11-hydroxyhexahydrocanna binol;
(R) HU-308[(91R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept -3-enyl]methanol;
(S) HU-3313-hydroxy-2-[(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;
(T) JTE-907N-(benzol[1,3]dioxol-5-ylmethyl) -7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide;
(U) JWH-051((6aR,10aR)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol;
(V) JWH-057(6aR,10aR)-3-(1,1-dimethylheptyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran;
(W) JWH-133(6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
(X) JWH-359 (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene;
(Y) URB-597[3-(3-carbamoylphenyl)phenyl] -N-cyclohexylcarbamate;
(Z) URB-602 [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexylester; or cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;
(AA) URB-7546-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one;
(BB) URB-937 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate;
(CC) WIN 55,212-2(R)-(+)-[2,3-dihydro-5-methyl-3- (4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin -6-yl]-1-napthalenylmethanone;
(DD) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
(EE) A M-694 (1-(5-fluoropentyl)- 3-(2- iodobenzoyl)indole);
(FF) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate ("PB-22"; QUPIC);
(GG) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate ("5-fluoro-PB-22"; 5F-PB-22);
(HH) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H -indazole-3-carboxamide ("AB-FUBINACA");
(II) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide ("ADB-PINACA");
(JJ) THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-1yl](naphthalen-1-yl)methanone;
(KK) (N-(1-amino-3-methyl-1- oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide ("AB-CHMINACA");
(LL) (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ("AB-PINACA");
(MM) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-fluoropentyl)-1H-indazole -3-carboxamide, (5F-AB-PINACA);
(NN) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide, (5F-ADBICA or 5F-ADB-PICA);
(OO) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, (5F-AMB or 5F-MMB-PINACA or 5F-AMB-PINACA); and
(PP) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H -indazole-3-carboxamide, N-(1-Adamantyl)-1-(5-fluoropenty1)-1 H-indazole-3-carboxarnide, (5F-APINACA or 5F-AKB48);
(g) Substituted tryptamines. This includes any compound, unless specifically excepted, specifically named in this schedule, or listed under a different schedule, structurally derived from 2-(1H-indol-3-yl) ethanamine (i.e., tryptamine) by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure regardless of whether the compound is further substituted at the alpha position with an alkyl group or further substituted on the indole ring to any extent with any a lkyl, alkoxy, halo, hydroxyl, or acetoxy groups. Examples include the following:
(1) (4-AcO-DET) 3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate (DET);
(2) (4-AcO-DMT, OAcetylpsilocin) 4-acetoxy-N,N-dimethyltryptamine;
(3) (4-AcO-DPT) 4-acetoxy-N,N -dipropyltryptamine;
(4) (4-HO-DiPT) 4-Hydroxy-di-isopropyl-tryptamine; OR 3-[2-(diisopropylamino)ethyl]-1H-indol-4-ol; OR 4-Hydroxy- N,N -diisopropyltryptamine;
(5) (4-HO-MET) 4-hydroxy-N-methyl-N-ethyltryptamine;
(6) (4-HO-MiPT) 3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol;
(7) (4-HO-MPMI) (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole;
(8) (4-HO-MPT) 3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol; OR 4- hydroxy-N-methyl-N-propyltryptamine;
(9) (4-MeO-MiPT) 4-methoxy-N-methyl-N-isopropyltryptamine; OR 3-[2 (Isopropylmethylamino)ethyl]-4-methoxyindole;
(10) 4-methyl-aET 4-Methyl-a-ethyltryptamine; OR 1-ethyl-2-(4-methyl-1H- indol-3-yl)-ethylamine;
(11) (5-MeO-AMT) 1-(5-methoxy-1H-indol-3-yl)propan-2-amine;
(12) (5-MeO-DALT) N,N-diallyl-5-methoxytryptamine; OR N-allyl-N-[2-(5- methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine;
(13) (5-MeO-DET) N,N -Dethyl-5-Methoxytryptamine;
(14) (5-MeO-DPT) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1- amine;
(15) (5-MeO-MiPT, Moxy, Moxie) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine;
(16) (5-MeO-MPMI) (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole;
(17) (DPT) N,N-Dipropyltryptamine; OR Dipropyltryptamine; OR 3-[2-(dipropylamino)ethyl]indole;
(18) (Methyltryptamine, NMT) N-methyltryptamine; OR 2-(1H-Indol-3-yl)-N-methylethanamine; and
(19) (MiPT) N-isopropyl-N-methyltryptamine;
(20) 2-(1H-indol-3-yl)-N-methyl-ethanamine;
(21) N-(2-(1H -indol-3-yl)ethyl-N-methylpropan-2-amine;
(22) N-[2-(1H-indol-3-yl)ethyl]-N-isopropylpropan-2-amine;
(23) N,N-dipropyl-1H-indole-3-ethanamine;
(24) 3-[2-(diethylamino)ethyl]-1H-4yl acetate;
(25) 3-(2-[isopropyl(methyl)amino]ethyl)-1H-indol-4-ol;
(26) 3-[2-(bis[1-methylethyl]amino)ethyl]-1H -indol-4-ol acetate;
(27) 3-(2-[isopropyl(methyl)amino]ethyl)-1H-indol-4-ol acetate;
(28) 3-[2-(dimethylamino)ethyl]-1H -indol-4-yl acetate;
(29) 4-hydroxy-N,N-diethyl-1H-indole-ethanamine;
(30) 4-methoxy-N,N-dimethyl-1H-indole -3-ethanamine;
(31) 3-(2-(diisopropylamino)ethyl)-1H-indol-4-ol;
(32) 3-[2-(ethyl[methyl]amino)ethyl]-1H-indol-4-yl acetate;
(33) 3-(2-(dipropylamino)ethyl)-1H -indol-4-ol;
(34) 3-[2-(dipropylamino)ethyl]-1H-indol-4-yl acetate;
(35) 4-acetoxy-N,N-di-2-propen-1-yl-1H -indole-3-ethanamine;
(36) 5-methoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine;
(37) 3-(2-(dimethylaminoethyl)-1H -indol-5-ol;
(38) 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine;
(39) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropyl;
(40) 1-(5-methoxy-1H-indol-3-yl)propan-2-amine;
(41) 3-[2-(dimethylamino)-ethyl]-1H -indol-5-yl acetate;
(42) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine;
(43) N,N-diethyl-2-(5-methoxy-1H-indol-3-yl)ethanamine; and
(44) N-ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methyl-ethanamine;
(h) Unclassified novel psychoactive substances
(1) (2-AI, 2-aminoindane) 2,3-dihydro-1H-inden-2-amine;
(2) (2-FMA) 2-fluoromethamphetamine; OR (RS)-1-(2-fluorophenyl)-N-methylpropan-2-amine; N-Methyl-1-(3-fluorophenyl)propan-2- amine;
(3) (2-MeO-ketamine) methoxyketamine;
(4) (3-HO-PCE) 3-[1-(ethylamino) cyclohexyl]phenol;
(5) (3-HO-PCP) 3-hydroxyphencyclidine (3-MeO-PCE) 3-Methoxyeticyclidine;
(6) (3-MeO-PCP) 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine; OR 3-methoxyphencyclidine;
(7) (4-FMA) 4-fluoromethamphetamine; OR (RS)-1-(4-fluorophenyl)-N-methylpropan-2-amine; N-Methyl-1-(4-fluorophenyl)propan-2-amine;
(8) (4-MeO-PCP, methoxydine) 4-Methoxyphencyclidine; OR 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine;
(9) (5-IAI) 5-Iodo-2-aminoindane; OR 5-iodo-2,3-dihydro-1H-inden-2-amine;
(10) (5-ME) 5-methyl-ethylone;
(11) (BTCP) Benzothiophenylcyclohexylpiperidine;
(12) (DBP, DBZP) 1,4-Dibenzylpiperazine;
(13) (Ethyl-ketamine) 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone;
(14) (Fluoromethamphetamine);
(15) (Fluorophenylpiperazine; pFPP; 4-FPP; fluoperazine; flipiperazine) Para-fluorophenylpiperazine; OR 1-(4-fluorophenyl)piperazine;
(16) (Kratom) 7-hydroxymitragynine;
(17) (MCPP) 1-(3-Chlorophe nyl)piperazine, OR Chlorophenylpiperazine, OR meta chlorophenylpiperazine; OR 1-(3-chlorophenyl)piperazine; OR 3-chlorophenylpiperazine;
(18) (Methiopropamine, MPA) 1-(thiophen-2-yl)-2-methylaminopropane; N-Methyl-1-(thiophen-2-yl)propan-2-amine;
(19) (Methoxetamine, MXE, 3 MeO-2-Oxo-PCE) (RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone;
(20) (MPHP) Methyl-alpha-pyrrolidinohexiophenone; OR Methyl-pyrrolidino-hexanophenone;
(21) (O-desmethyltramadol, O-DT) 3-[2-(1-Amino-1-methylethyl)-1-hydroxycyclohexyl]phenol;
(22) (Phenazepam) 7-Bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;
(23) (pMeOPP, MeOPP) 1-(4-Methoxyphenyl) piperazine;
(24) (pTFMPP) 1-[4-(trifluoromethylphenyl)] piperazine;
(25) (TFMPP) 3-trifluoromethylphenylpiperazine; OR 1-[3-(trifluoromethyl)phenyl]piperazine; OR 1-(3-trifluoromethylphenyl) piperazine; OR 1-(3-trifluoromethylphenyl)piperazine; OR 1-(3-[trifluoromethylphenyl])piperazine.
(26) (±)-2,5-Dimethoxy-alpha-methylphenethylamine, (DMA);
(27) 6,6,9-Trimethyl-3-(3-methyl-2-octanyl)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol, (DMHP), Dimethylheptylpyran;
(28) 3-(2-(Dimethylamino)ethyl)indole, (DMT);
(29) P-methoxy-alpha-methylphenethylamine, (PMA);
(30) Methylenedioxyamphetamine, 3,4-methylenedioxy-amphetamine, MDA, tenamfetamine (INN), Sally, Sass, Sass-a-frass;
(31) Tenocyclidine (TCP);
(32) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-l-(5-fluoropenty1)-1H-indole-3-carboxamide, (5F-ABICA);
(33) [1-(2-morpholin-4-ylethyl) -1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl) methanone, (A-796,260);
(34) N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, (AB-CHMINACA);
(35) (4-F-a-PVP) 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)pentan-1-one;
(36) (4-MeBP) 1-(4-Methylphenyl)-2-methylaminobutan-1-one;
(37) (4-MeO-a-PVP) 1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)pentan-1-one;
(38) (NEB) 1-phenyl-2-ethylaminobutan-1-one;
(39) (a-PHP) 1-phenyl-2-(1-pyrrolidinyl)hexan-1-one;
(40) (a-PHPP) 1-phenyl-2-(1-pyrrolidinyl)heptan-1-one;
(41) (a-PVT) 1-(thiophen-2-yl) -2-(1-pyrrolidinyl)pentan-1-one;
(42) (NENK) 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone ;
(43) (5-MeO-DMT) 5-methoxy-N,N-dimethyltryptamine;
(44) (AMT) alpha-methyltryptamine;
(45) (3,4-CTMP) methyl 2-(3,4-dichlorophenyl)-2-(piperdin-2-yl);
(46) (AH-7921) 3,4-dichloro-N-((1-(dimethylamino)cyclohexyl)methyl)benzamide;
(47) (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone;
(48) 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone;
(49) 1-[1-(2-cyclohexylethyl)-1H -indol-3-yl]-2-(2-methoxyphenyl)-Ethanone;
(50) [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)methanone;
(51) (2-methyl-1-[(1-methylpiperidin-2-yl)methyl]-6-nitro-1H-indol-3-yl)methanone; and
(52) (1-butyl-1H -indol-3-yl)(4-methoxyphenyl)-methanone .
(i) Synthetic compounds:
(1) MT-45 (1-Cyclohexyl-4-(1,2- diphenylethyl) piperazine;
(2) U-47700 (3,4-Dichloro- N -[(1 R ,2 R)-2-(dimethylamino) cyclohexyl]- N -methylbenzamide; and
(3) W-1 4-chloro-N-[(2Z)-1-[2-(4 -nitrophenyl)ethyl]piperidin-2- ylidene]benzene-1-sulfonamide.

D.C. Mun. Regs. tit. 22, r. 22-B1201

Final Rulemaking published at 39 DCR 1882 (March 20, 1992); as amended by Final Rulemaking published at 41 DCR 7967 (December 16, 1994); and by the Uniform Controlled Substances Amendment Act of 1999 §2(a)(3), D.C. Act 13-245, 47 DCR 791 (February 11, 2000); Notice of Emergency and Proposed Rulemaking published at 47 DCR 7512 (September 15, 2000) [EXPIRED]; as amended by Final Rulemaking published at 48 DCR 914 (February 2, 2001); as amended by Notice of Emergency and Proposed Rulemaking published at 50 DCR 10421 (December 5, 2003) [EXPIRED]; as amended by Final Rulemaking published at 51 DCR 4080 (April 23, 2004); as amended by Final Rulemaking published at 61 DCR 10233 (October 3, 2014); amended by Final Rulemaking published at 63 DCR 014819 (12/2/2016); amended by Final Rulemaking published at 64 DCR 635 (1/26/2018, as corrected by Errata by Final Rulemaking published at 64 DCR 1633 (2/16/2018)